These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 15371830)

  • 21. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
    Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
    J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preoperative neural network using combined magnetic resonance imaging variables, prostate specific antigen and Gleason score to predict prostate cancer stage.
    Poulakis V; Witzsch U; De Vries R; Emmerlich V; Meves M; Altmannsberger HM; Becht E
    J Urol; 2004 Oct; 172(4 Pt 1):1306-10. PubMed ID: 15371829
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quantitative immunohistochemical determination of cathepsin D levels in prostatic carcinoma biopsies. Correlation with tumor grade, stage, PSA level, and DNA ploidy status.
    Ross JS; Nazeer T; Figge HL; Fisher HA; Rifkin MD
    Am J Clin Pathol; 1995 Jul; 104(1):36-41. PubMed ID: 7541934
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gleason score 7 prostate cancer on needle biopsy: is the prognostic difference in Gleason scores 4 + 3 and 3 + 4 independent of the number of involved cores?
    Makarov DV; Sanderson H; Partin AW; Epstein JI
    J Urol; 2002 Jun; 167(6):2440-2. PubMed ID: 11992053
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evidence of increased failure in the treatment of prostate carcinoma patients who have perineural invasion treated with three-dimensional conformal radiation therapy.
    Bonin SR; Hanlon AL; Lee WR; Movsas B; al-Saleem TI; Hanks GE
    Cancer; 1997 Jan; 79(1):75-80. PubMed ID: 8988729
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men.
    Catalona WJ; Richie JP; Ahmann FR; Hudson MA; Scardino PT; Flanigan RC; DeKernion JB; Ratliff TL; Kavoussi LR; Dalkin BL; Waters WB; MacFarlane MT; Southwick PC
    J Urol; 1994 May; 151(5):1283-90. PubMed ID: 7512659
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of DNA ploidy combined with a cytometric proliferation index of imprints from core needle biopsies in prostate cancer.
    Ahlgren G; Falkmer U; Gadaleanu V; Abrahamsson PA
    Eur Urol; 1999 Oct; 36(4):314-9. PubMed ID: 10473991
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prostate cancers diagnosed at repeat biopsy are smaller and less likely to be high grade.
    Tan N; Lane BR; Li J; Moussa AS; Soriano M; Jones JS
    J Urol; 2008 Oct; 180(4):1325-9; discussion 1329. PubMed ID: 18707706
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer.
    D'Amico AV; Whittington R; Malkowicz SB; Schultz D; Schnall M; Tomaszewski JE; Wein A
    J Urol; 1995 Jul; 154(1):131-8. PubMed ID: 7539857
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Histopathological findings in extended prostate biopsy with PSA < or = 4 ng/mL.
    Leite KR; Srougi M; Dall'Oglio MF; Sanudo A; Camara-Lopes LH
    Int Braz J Urol; 2008; 34(3):283-90; discussion 290-2. PubMed ID: 18601758
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Value of determining prostate-specific antigen for early detection or prostatic carcinoma].
    Hammerer P; Huland H
    Urologe A; 1995 Jul; 34(4):283-9. PubMed ID: 7545842
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng./ml.: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests.
    Mäkinen T; Tammela TL; Hakama M; Stenman UH; Rannikko S; Aro J; Juusela H; Määttänen L; Auvinen A
    J Urol; 2001 Oct; 166(4):1339-42. PubMed ID: 11547069
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic significance of preoperative factors in localized prostate carcinoma treated with radical prostatectomy: importance of percentage of biopsies that contain tumor and the presence of biopsy perineural invasion.
    Quinn DI; Henshall SM; Brenner PC; Kooner R; Golovsky D; O'Neill GF; Turner JJ; Delprado W; Grygiel JJ; Sutherland RL; Stricker PD
    Cancer; 2003 Apr; 97(8):1884-93. PubMed ID: 12673714
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prediction of extraprostatic extension in the neurovascular bundle based on prostate needle biopsy pathology, serum prostate specific antigen and digital rectal examination.
    Tsuzuki T; Hernandez DJ; Aydin H; Trock B; Walsh PC; Epstein JI
    J Urol; 2005 Feb; 173(2):450-3. PubMed ID: 15643200
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Flow cytometric DNA analysis of fresh prostatic resections. Correlation with conventional prognostic parameters in patients with prostate cancer.
    Hussain MH; Powell I; Zaki N; Maciorowski Z; Sakr W; KuKuruga M; Visscher D; Haas GP; Pontes JE; Ensley JF
    Cancer; 1993 Nov; 72(10):3012-9. PubMed ID: 7693326
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves.
    Catalona WJ; Richie JP; deKernion JB; Ahmann FR; Ratliff TL; Dalkin BL; Kavoussi LR; MacFarlane MT; Southwick PC
    J Urol; 1994 Dec; 152(6 Pt 1):2031-6. PubMed ID: 7525994
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prospective evaluation of prostate specific antigen and prostate specific antigen density in the detection of nonpalpable and stage T1C carcinoma of the prostate.
    Presti JC; Hovey R; Carroll PR; Shinohara K
    J Urol; 1996 Nov; 156(5):1685-90. PubMed ID: 8863571
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Deoxyribonucleic acid ploidy analysis as a predictor of recurrence following radical prostatectomy for stage T2 disease.
    Carmichael MJ; Veltri RW; Partin AW; Miller MC; Walsh PC; Epstein JI
    J Urol; 1995 Mar; 153(3 Pt 2):1015-9. PubMed ID: 7853549
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Saturation biopsy technique increase the capacity to diagnose adenocarcinoma of prostate in patients with PSA < 10 ng/ml, after a first negative biopsy.
    Giulianelli R; Brunori S; Gentile BC; Vincenti G; Nardoni S; Pisanti F; Shestani T; Mavilla L; Albanesi L; Attisani F; Mirabile G; Schettini M
    Arch Ital Urol Androl; 2011 Sep; 83(3):154-9. PubMed ID: 22184840
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Perineural invasion as a predictor of biochemical outcome following radical prostatectomy for select men with clinically localized prostate cancer.
    D'Amico AV; Wu Y; Chen MH; Nash M; Renshaw AA; Richie JP
    J Urol; 2001 Jan; 165(1):126-9. PubMed ID: 11125380
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.